Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Conditions
Interventions
GRF6021
Placebo
Locations
29
United States
Clinical Trials, Inc.
Little Rock, Arkansas, United States
Rocky Mountain Movement Disorders Center
Englewood, Colorado, United States
Moonshine Research Center
Doral, Florida, United States
Riverside Clinical Research
Edgewater, Florida, United States
MD Clinical
Hallandale, Florida, United States
Research Centers of America, LLC
Hollywood, Florida, United States
Start Date
November 12, 2018
Primary Completion Date
July 20, 2020
Completion Date
July 20, 2020
Last Updated
May 9, 2022
NCT07187843
NCT07545473
NCT07543861
NCT05748028
NCT07495462
NCT04876339
Lead Sponsor
Alkahest, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions